XERIS BIOPHARMA HOLDINGS, INC. Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount of $142.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-06.
Discontinued › Notes › Income Taxes
us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount · last filed 2024-03-06
- XERIS BIOPHARMA HOLDINGS, INC. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2023 was $142.00K, a 65.70% decline from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2022 was $414.00K, a 54.05% decline from fiscal 2021.
- XERIS BIOPHARMA HOLDINGS, INC. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2021 was $901.00K, a 11.14% decline from fiscal 2020.
- XERIS BIOPHARMA HOLDINGS, INC. effective income tax rate reconciliation, tax expense (benefit), share-based payment arrangement, amount for fiscal 2020 was $1.01M.
| Period end | Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2023-12-31 | $142.00K 10-K · filed 2024-03-06 |
| 2022-12-31 | $414.00K 10-K · filed 2024-03-06 |
| 2021-12-31 | $901.00K 10-K · filed 2024-03-06 |
| 2020-12-31 | $1.01M 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |